Nanotechnology Now - Press Release: Advanced Magnetics to Host Earnings Conference Call to Discuss Second Fiscal Quarter Results

Home > Press > Advanced Magnetics to Host Earnings Conference Call to Discuss Second Fiscal Quarter Results

Abstract:
Advanced Magnetics, Inc. (Nasdaq: AMAG) today announced that it will report second
fiscal quarter 2007 financial results after the U.S. financial markets
close on Wednesday, April 25, 2007. The announcement will be followed by a
conference call at 4:30 p.m. ET during which management will discuss the
company's financial results, quarterly highlights and clinical development
programs.

Advanced Magnetics to Host Earnings Conference Call to Discuss Second Fiscal Quarter Results

Cambridge, MA | Posted on April 12th, 2007

An audio webcast of the earnings call will be available through the
Investors section of the company's website at http://www.advancedmagnetics.com .
The webcast will also be available as a replay, starting approximately one
hour after the call is completed, through May 25, 2007.

To access the conference call via telephone, please dial (800) 819-9193
from the United States or (913) 981-4911 for international access. A
telephone replay will be available from approximately 7:30 p.m. ET on April
11 through April 12. To access a replay of the conference call, dial (888)
203-1112 from the United States or (719) 457-0820 for international access.
The passcode for both replay numbers is of 5320343.

####

About Advanced Magnetics
About Advanced Magnetics

Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products. As a leader in our field, we
are dedicated to the development and commercialization of our proprietary
nanoparticle technology for use in therapeutic iron compounds to treat
anemia, as well as novel imaging agents to aid in the diagnosis of
cardiovascular disease and cancer.

Ferumoxytol, the company's key product candidate, is being developed
for use as an intravenous iron replacement therapeutic for the treatment of
iron deficiency anemia in chronic kidney disease. The company plans to file
a New Drug Application for marketing approval of ferumoxytol with the U.S.
Food and Drug Administration during the fourth calendar quarter of 2007.

Combidex(R), the company's second product under development, is an
investigational functional molecular imaging agent consisting of iron oxide
nanoparticles for use in conjunction with magnetic resonance imaging, or
MRI, to aid in the differentiation of cancerous from normal lymph nodes. In
March 2005, the company received an approvable letter from the FDA with
respect to Combidex, subject to certain conditions.